Precision Bio Says USPTO Issues Final Claims Rejecting Infringement Allegations by Cellectis | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Precision BioSciences today announced that in a reexamination proceeding the US Patent and Trademark Office has rejected claims by Cellectis that Precision infringed on four of its patents.

The USPTO issued its Final Decisions and Right of Appeal Notices in the reexamination of US Patent Nos. 6,833,252; 7,214,536; 6,610,545; and 7,309,605. The patents are owned by the Institut Pasteur and the Universite Pierre et Marie Curie and licensed to Cellectis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.